English
简体中文
Total: £ 56.28
2026-01-22 | Pages: 125 | Tables: 120
The global Niche Active Pharmaceutical Ingredients (API) and Intermediates market was valued at US$ 5338 million in 2025 and is anticipated to reach US$ 10150 million by 2032, at a CAGR of 9.8% from 2026 to 2032.The 2025 U.S. tariff policies introduc...
2026-01-22 | Pages: 133 | Tables: 134
The global New Chemical Entities (NCE) market was valued at US$ 4992 million in 2025 and is anticipated to reach US$ 10420 million by 2032, at a CAGR of 11.2% from 2026 to 2032.During the drug discovery process, new compounds or active moieties (mole...
2026-01-22 | Pages: 119 | Tables: 113
The global New Chemical Entities (NCE) CDMO market was valued at US$ 3242 million in 2025 and is anticipated to reach US$ 6811 million by 2032, at a CAGR of 11.4% from 2026 to 2032.New Chemical Entities (NCE) refer to new compounds that have not yet ...
2026-01-22 | Pages: 109 | Tables: 103
The global Value-added Medicines (VAM) Development Service market was valued at US$ 638 million in 2025 and is anticipated to reach US$ 1269 million by 2032, at a CAGR of 10.5% from 2026 to 2032.Value-added Medicines Development Service usually ref...
2026-01-22 | Pages: 111 | Tables: 113
The global Value-added Medicines (VAM) market was valued at US$ 842 million in 2025 and is anticipated to reach US$ 1759 million by 2032, at a CAGR of 11.3% from 2026 to 2032.Value-added medicines offer the medical world the opportunity to increase t...
2026-01-22 | Pages: 140 | Tables: 124
The global First-in-Human (FIH) Services market was valued at US$ 751 million in 2025 and is anticipated to reach US$ 1576 million by 2032, at a CAGR of 11.3% from 2026 to 2032.First-in-Human Services refer to specialized services that support the pl...
2026-01-22 | Pages: 118 | Tables: 119
The global Clinical Trial Manufacturing Service market was valued at US$ 1211 million in 2025 and is anticipated to reach US$ 1630 million by 2032, at a CAGR of 4.4% from 2026 to 2032.Clinical trial manufacturing service is a service that provides cu...
2026-01-22 | Pages: 205 | Tables: 185
The global iPSC Cell Therapies market was valued at US$ 10400 million in 2025 and is anticipated to reach US$ 21950 million by 2032, at a CAGR of 11.4% from 2026 to 2032.Induced pluripotent stem cell (iPSC) cell therapy is a cutting-edge regenerative...
2026-01-22 | Pages: 115 | Tables: 114
The global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services market was valued at US$ 537 million in 2025 and is anticipated to reach US$ 1026 million by 2032, at a CAGR of 9.8% from 2026 to 2032.Proteolysis Targeting Chim...
2026-01-22 | Pages: 113 | Tables: 112
The global Dosage Form Development Service market was valued at US$ 1294 million in 2025 and is anticipated to reach US$ 1910 million by 2032, at a CAGR of 5.8% from 2026 to 2032.Dosage form development service refers to research and development serv...
2026-01-22 | Pages: 112 | Tables: 116
The global Commercial Drug Manufacturing Service market was valued at US$ 1929 million in 2025 and is anticipated to reach US$ 2809 million by 2032, at a CAGR of 5.6% from 2026 to 2032.Commercial drug manufacturing service refers to a series of manuf...
2026-01-22 | Pages: 108 | Tables: 117
The global Cytotoxic T Cells (CTL) market was valued at US$ 95.59 million in 2025 and is anticipated to reach US$ 166 million by 2032, at a CAGR of 8.3% from 2026 to 2032.The 2025 U.S. tariff policies introduce profound uncertainty into the global ec...
2026-01-22 | Pages: 111 | Tables: 113
The global Extracellular Vesicle Therapy market was valued at US$ 988 million in 2025 and is anticipated to reach US$ 1958 million by 2032, at a CAGR of 10.4% from 2026 to 2032.Extracellular Vesicle Therapy refers to an emerging therapy that uses ext...
2026-01-22 | Pages: 122 | Tables: 124
The global Chinese Hamster Ovary Cell Line market was valued at US$ 336 million in 2025 and is anticipated to reach US$ 551 million by 2032, at a CAGR of 7.4% from 2026 to 2032.The 2025 U.S. tariff policies introduce profound uncertainty into the glo...
2026-01-22 | Pages: 116 | Tables: 114
The global Induced Pluripotent Stem Cells Service market was valued at US$ 3223 million in 2025 and is anticipated to reach US$ 6387 million by 2032, at a CAGR of 10.4% from 2026 to 2032.Induced pluripotent stem cell (iPSC) services refer to a series...
